.png){kind=icon}
返回
Systemic lupus erythematosus
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(24)00398-2.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterised by the presence of autoantibodies towards nuclear antigens, immune complex deposition, and chronic inflammation at classic target organs such as skin, joints, and kidneys. Despite substantial advances in the diagnosis and management of SLE, the burden of disease remains high. It is important to appreciate the typical presentations and the diagnostic process to facilitate early referral and diagnosis for patients. In most patients, constitutional, mucocutaneous, and musculoskeletal symptoms represent the earliest complaints; these symptoms can include fatigue, lupus-specific rash, mouth ulcers, alopecia, joint pain, and myalgia. In this Seminar we will discuss a diagnostic approach to symptoms in light of the latest classification criteria, which include a systematic evaluation of clinical manifestations (weighted within each domain) and autoantibody profiles (such as anti-double-stranded DNA, anti-Sm, hypocomplementaemia, or antiphospholipid antibodies). Non-pharmacotherapy management is tailored to the individual, with specific lifestyle interventions and patient education to improve quality of life and medication (such as hydroxychloroquine or immunosuppressant) adherence. In the last decade, there have been a few major breakthroughs in approved treatments for SLE and lupus nephritis, such as belimumab, anifrolumab, and voclosporin. However the disease course remains variable and mortality unacceptably high. Access to these expensive medications has also been restricted across different regions of the world. Nonetheless, understanding of treatment goals and strategies has improved. We recognise that the main goal of treatment is the achievement of remission or low disease activity. Comorbidities due to both disease activity and treatment adverse effects, especially infections, osteoporosis, and cardiovascular disease, necessitate vigilant prevention and management strategies. Tailoring treatment options to achieve remission, while balancing treatment-related comorbidities, are priority areas of SLE management.
Keyword:
MYCOPHENOLATE-MOFETIL
RHEUMATOID-ARTHRITIS
CONTROLLED-TRIAL
CUTANEOUS LUPUS
DOUBLE-BLIND
SLE
HYDROXYCHLOROQUINE
CYCLOPHOSPHAMIDE
PREVALENCE
EFFICACY
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
引用论文
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialVoslosporin与安慰剂治疗狼疮性肾炎 (AURORA 1) 的疗效和安全性: 一项双盲，随机，多中心，安慰剂对照的3期试验.png)
LANCET
LANCETIF88.5
PREAI
分享收藏Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK自身免疫性疾病和心血管风险: 一项基于人群的研究，涉及英国2200万个人的19种自身免疫性疾病和12种心血管疾病LANCET
OAAI
LANCETIF88.5
OAAI分享收藏Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trialsLANCET RHEUMATOLOGY
LANCET RHEUMATOLOGYIF16.4
PREAI
分享收藏
查看更多内容